Tag - JAK

Provider Alert!

Provider Alert! Clinical Criteria Revision for Cibinqo Effective May 31, 2023

Date: April 25, 2023 Attention: All Providers Effective Date: May 31, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective May 31, 2023, the Health and Human Services Commission (HHSC) will expand coverage for Cibinqo to adolescents 12-18 years of age due to a recent U.S. Food and Drug Administration (FDA) approval. Cibinqo belongs to a class of medications called Janus Kinase (JAK) Inhibitors and is indicated for the treatment of adults with refractory moderate-to-severe atopic...